Table 1: Incidence rates and hazard ratios
AG, Andersen-Gill; GLM, golimumab; bDMARD, biologic disease-modifying anti-rheumatic drug; csDMARD, conventional synthetic disease-modifying anti-rheumatic; IR, incidence rate; PY, patient years; CI, confidence interval; HR, hazard ratio
N= number of participants exposed to respective treatment
Treatment episodes = number of initiations with respective treatment
aIn the Andersen-Gill model (extended Cox regression model), recurrent events were taken into account, therefore event numbers can be higher than with incidence rates.
bCovariates in the model included propensity score based inverse probability of treatment weights: age, sex (male vs female), RA disease duration in years, RF/ACPA (no vs yes), year of treatment start (</=2012), DAS28, FFbH, previous bDMARDs b (0/1 vs =2), glucocorticoid dosage (<5 vs 5-<10 / =10 mg/day), smoking (never vs ever +unknown), COPD (no vs yes; for serious infections), chronic renal disease (no vs yes; for serious infections), diabetes (no vs yes; for all-cause mortality), chronic renal disease (no vs yes; for all-cause mortality), history of heart failure (no vs yes; for all-cause mortality), chronic heart disease (no vs yes; for all-cause mortality)
cHR not calculated due to only 1 event of demyelinating disorders occurring in GLM group.